--- title: Moderna's Omicron Booster Increases Antibody Levels description: The vaccine, made by Moderna, is the first to combine the original vaccine with a new version that targets Omicron. Here's what to know. canonical: https://time.com/6185406/omicron-booster-moderna/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2022-06-08T14:54:06.000Z article:modified_time: 2026-02-24T14:21:14.194Z article:section: Health og:title: Omicron-Specific Booster Increases Antibody Levels, Moderna Says og:description: The vaccine is the first to combine the original vaccine with a new version that targets Omicron og:url: https://time.com/6185406/omicron-booster-moderna/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt414f35ccd2784343/698a329ddb29875d1d267e34/GettyImages-1303673697.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2121 og:image:height: 1193 og:image:alt: Covid-19 Vaccine og:type: article twitter:card: summary_large_image twitter:title: Omicron-Specific Booster Increases Antibody Levels, Moderna Says twitter:description: The vaccine is the first to combine the original vaccine with a new version that targets Omicron twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt414f35ccd2784343/698a329ddb29875d1d267e34/GettyImages-1303673697.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Omicron-Specific Booster Increases Antibody Levels, Moderna Says > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=592f633b-d7ef-46bd-b6d7-26e8d64a1f60&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=592f633b-d7ef-46bd-b6d7-26e8d64a1f60&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=592f633b-d7ef-46bd-b6d7-26e8d64a1f60&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Jun 8, 2022 2:54 PM UTC  Brasov, Romania - February 21, 2021: Moderna Covid-19 vaccine on a white background. Brasov, Romania - February 21, 2021: Moderna Covid-19 vaccine on a white background. Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Jun 8, 2022 2:54 PM UTC Public-health experts have long warned that a new vaccine against the SARS-CoV-2 virus might be needed—especially now that the Omicron variant and its many subvariants are causing the vast majority of new COVID-19 cases around the world. There may soon be one. Moderna, which makes one of the three COVID-19 vaccines authorized by the U.S. Food and Drug Administration (FDA), announced results from its study of a new vaccine the company’s scientists developed that targets both the original virus strain as well as Omicron. Combining the two strains in a booster dose produced an average of eight times the levels of virus-neutralizing antibodies targeted against both Omicron and the original virus in vaccinated people, compared to those boosted with the original vaccine, the company [reported](https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx) in a press release. Scientists have said that the original two-dose shot and its booster doses continue to significantly protect people from severe disease and hospitalization, even against the different variants that have emerged since the shots were developed. But the levels of antibodies that vaccinated people generate against Omicron are generally lower than those produced against the original virus. In response, vaccine manufacturers including Moderna have developed combination, or bivalent, vaccines to enhance protection against Omicron. The company’s study shows that targeting both the original and Omicron strains leads to a stronger immune response. “We believe the data unequivocally show that the bivalent vaccine is significantly superior in producing neutralizing protection,” Moderna president Dr. Stephen Hoge said during a conference call announcing the results. “To more accurately reflect the circulating strain \[of the virus\], the data clearly show that it’s time to update the vaccine to improve the durability and magnitude of protection for the coming fall.” **Read More**: [_Here’s What to Know About COVID-19 Booster Shots for Kids_](https://time.com/6183609/kids-covid-19-boosters-when-to-get/) Whether the original vaccine needs to be changed to one such as the Omicron-targeting shot will be up to the FDA to decide. Over the next few weeks, Moderna plans to submit its latest data to the agency in order to seek authorization for its bivalent vaccine as a booster dose, which might be recommended for people in the fall. This is the company’s second combination vaccine; earlier this spring, Moderna scientists [released similarly encouraging data](https://time.com/6168232/multi-strain-covid-19-vaccines-moderna/) showing that a vaccine targeting both the original strain of SARS-CoV-2 and the Beta variant generated higher amounts of virus-neutralizing antibodies against a number of different virus strains, including the original, Beta, and Omicron variants. Hoge noted, however, that the data only extend to one month after the booster dose, so the company is continuing to follow the study participants to track how durable that protection is. “The real goal is to get to six or nine months of protection, which gets you through the respiratory season,” he says of the fall and winter, when viruses like influenza and coronaviruses tend to circulate more as people spend more time indoors. Currently, protection from the original Moderna booster wanes after about four to five months, which is why health officials recommend that everyone who has been vaccinated receive at least one booster dose four to five months after completing the primary two-dose regimen, and that some people at higher risk get boosted yet again with an additional dose. The combination booster has not yet been tested in children, but Hoge said those studies will now begin, given the reassuring safety and efficacy data from the booster in adults. The FDA has not yet reviewed Moderna’s application for authorizing its original vaccine in children; the [agency’s advisory committee will be meeting](https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcement) on June 14 and 15 to review Moderna’s data for pediatric COVID-19 vaccines to make a recommendation. The same committee will meet on June 28 to discuss whether [new formulations of COVID-19 vaccines](https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement), such as Moderna’s Omicron combination booster, should be recommended as a booster dose for adults in the fall, and whether the combination vaccine should replace the original vaccine for those who haven’t been vaccinated yet. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6185406/omicron-booster-moderna/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6185406/omicron-booster-moderna/"},"headline":"Omicron-Specific Booster Increases Antibody Levels, Moderna Says","datePublished":"2022-06-08T14:54:06.000Z","dateModified":"2026-02-24T14:21:14.194Z","description":"The vaccine is the first to combine the original vaccine with a new version that targets Omicron","url":"https://time.com/6185406/omicron-booster-moderna/","keywords":["COVID-19","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt414f35ccd2784343/698a329ddb29875d1d267e34/GettyImages-1303673697.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt414f35ccd2784343/698a329ddb29875d1d267e34/GettyImages-1303673697.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Covid-19 Vaccine","caption":"Covid-19 Vaccine","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6185406/omicron-booster-moderna/","name":"Omicron-Specific Booster Increases Antibody Levels, Moderna Says"}}]}] ```